← aTYR PHARMA INC (ATYR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
aTYR PHARMA INC (ATYR)
Biological Products, (No Diagnostic Substances) · market cap $34M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
aTyr Pharma (Nasdaq: LIFE) is a micro-cap biotherapeutics company with a $52M market cap and approximately 55 employees, focused on tRNA synthetase biology. Its lead asset ATYR1940 is in Phase 2 for Facioscapulohumeral Muscular Dystrophy (FSHD), while the company previously described ATYR1923 as its lead ILD candidate — the current pipeline listing centers solely on ATYR1940. With only $10M cash and a stated runway of roughly 2.4 months, the company faces acute near-term financing risk.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ATYR1940 | Phase 2 | Facioscapulohumeral Muscular Dystrophy (FSHD) |
Price & technical context
3-month
-55.4%
6-month
-65.9%
12-month
-58.0%
52-wk range
$0.29–$1.06
vs 50-day MA
-36.7%
vs 200-day MA
-56.0%
Realized vol
112.4%
Max drawdown
-95.6%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ATYR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.